Impact of Remdesivir on inflammatory and prognostic markers of COVID-19: Findings of an event-monitoring study
Authors:
Open Access
- 21 December 2023
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Family Medicine and Primary Care
- Vol. 12 (12) , 3135-3141
Abstract
Introduction: Remdesivir is currently approved for treating hospitalised patients with COVID-19. However, it is a priority to monitor its safety and effectiveness in various clinical settings. This study was undertaken to assess the impact of remdesivir on inflammatory and prognostic markers of COVID-19. Materials and Methods: A hospital-based prospective longitudinal study was conducted over two months comprising event monitoring of COVID-19 patients administered remdesivir as per standard guidelines. The demographic details, risk factors and all baseline parameters were collected. The patients were followed up for the appearance of any adverse drug reactions (ADRs) after the start of remdesivir therapy from Day 1 to discharge or death every day. Repeat Lab tests were done on days 2, 4, 6 and 10 days to assess the impact of remdesivir on inflammatory and prognostic markers of COVID-19 over time. Significant predictors of survival in the cohort were also assessed. Results: A total of 60 COVID-19 patients were administered remdesivir. The mean age of the patients was 59.2 (+13.7) years. There was a significant improvement in the serum creatinine (decreased from 0.9 to 0.7 mg/dL), lymphocyte count {decreased from 9.2 to 7.3 (10 9 cells/L)} and serum sodium (increased from 134.6 to 137.4) of the patients over six days after the administration of remdesivir. The significant survival predictors were multiple organ failure ( P 0.046) and WBC count on Day 10 ( P 0.001). Conclusion: Remdesivir administration improved the prognostic biomarker profile in COVID-19 patients.Keywords
This publication has 30 references indexed in Scilit:
- Repurposed Antiviral Drugs for Covid-19 — Interim WHO Solidarity Trial ResultsNew England Journal of Medicine, 2021
- Remdesivir for 5 or 10 Days in Patients with Severe Covid-19New England Journal of Medicine, 2020
- Remdesivir — An Important First StepNew England Journal of Medicine, 2020
- Remdesivir for the Treatment of Covid-19 — Final ReportNew England Journal of Medicine, 2020
- Safety profile of the antiviral drug remdesivir: An updateBiomedicine & Pharmacotherapy, 2020
- Interventions for treatment of COVID-19: A living systematic review with meta-analyses and trial sequential analyses (The LIVING Project)PLOS Medicine, 2020
- An inflammatory cytokine signature predicts COVID-19 severity and survivalNature Medicine, 2020
- Compassionate remdesivir treatment of severe Covid-19 pneumonia in intensive care unit (ICU) and Non-ICU patients: Clinical outcome and differences in post-treatment hospitalisation statusPharmacological Research, 2020
- Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2Nature, 2020
- Discovery and Synthesis of a Phosphoramidate Prodrug of a Pyrrolo[2,1-f][triazin-4-amino] Adenine C-Nucleoside (GS-5734) for the Treatment of Ebola and Emerging Viruses2017